Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efavirenz + lamivudine + stavudine
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**efavirenz + lamivudine + stavudine** is a combination antiretroviral regimen used in the treatment of HIV-1 infection. It combines three agents with distinct mechanisms of action: efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI); lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI); and stavudine, also an NRTI. This regimen is particularly notable for use as a first-line therapy in resource-limited settings. Efavirenz inhibits HIV-1 reverse transcriptase by binding to an allosteric site, leading to disruption of enzyme activity. Both lamivudine and stavudine are incorporated into viral DNA by reverse transcriptase, resulting in chain termination and inhibition of viral replication[3][1].
- Brand names
- Virolis-E
- Other names
- lamivudine + efavirenz + stavudine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on efavirenz + lamivudine + stavudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efavirenz + lamivudine + stavudine.